BRAF-mutated Metastatic Colorectal Cancer Between Past and Future

British Journal of Cancer - United Kingdom
doi 10.1038/bjc.2015.316
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup

Frontiers in Oncology
Cancer ResearchOncology
2020English

RAS and BRAF in Metastatic Colorectal Cancer Management

Journal of Gastrointestinal Oncology
OncologyGastroenterology
2016English

Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients

Clinical Cancer Research
Cancer ResearchOncology
2015English

Future of Targeted Agents in Metastatic Colorectal Cancer

Colorectal Cancer
OncologyGastroenterology
2012English

CpG Island Methylation in Colorectal Cancer: Past, Present and Future

Pathology Research International
Forensic MedicinePathology
2011English

Correlation Between Tumor-Specific Mutated and Methylated DNA in Colorectal Cancer

JCO Precision Oncology
Cancer ResearchOncology
2019English

Correction: Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma

PLoS ONE
Multidisciplinary
2015English

T Cell-Engaging BiTE Antibodies Specific for EGFR Potently Eliminate KRAS- And BRAF-mutated Colorectal Cancer Cells

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2010English

Prevalence of KRAS, BRAF, PI3K and EGFR Mutations Among Asian Patients With Metastatic Colorectal Cancer

Oncology Letters
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy